This is the first and only oral JAK inhibitor indicated for giant cell arteritis, according to the manufacturer AbbVie. Medscape Medical News
Tag: Rheumatology
Slow Adalimumab Tapering May Cut Risk for Uveitis Relapse
A retrospective cohort analysis shows that pediatric patients with noninfectious uveitis face lower recurrence rates when adalimumab is tapered slowly after remission. Medscape Medical News
JAK Inhibitors Offer Some Improvement for Pediatric Uveitis
Only half of patients showed clinical improvement attributed to the medication, but only one new complication occurred. Medscape Medical News
FDA Approves First and Only Therapy for IgG4-RD
The CD19+ B-Cell targeted therapy reduced flare risk by 87% in a phase 3 clinical trial. Medscape Medical News
HLA-B27 Status Linked to Poor Outcomes in JIA After 18 Years
HLA-B27 positivity is linked to higher odds of non-remission in patients with juvenile idiopathic arthritis at 18 years after disease onset, with the odds being higher in men than in women. Medscape News UK
Inflammation Often Remains Following Tocilizumab Use for GCA
A recent study found that combined tocilizumab and glucocorticoid therapy for at least 6 months did not fully eliminate vascular inflammation in patients with giant cell arteritis. Medscape Medical News
Adalimumab: To Stop or Not to Stop for JIA-Linked Uveitis?
Patients with JIA-associated uveitis who discontinued adalimumab had higher recurrence rates than those who continued the treatment, but they regained control upon restarting it. Medscape Medical News
B-Cell Depleting Drug Shines in IgG4-Related Disease
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan condition. Medscape Medical News
Infliximab vs Adalimumab: Which Is Best for Behçet Syndrome?
Both infliximab and adalimumab were found to be effective in achieving remission and enhancing quality of life while having a high level of tolerability in patients with mucocutaneous Behçet syndrome. Medscape Medical News
IV Steroids in GCA: No Visual Benefit, Higher Diabetes Risk
Intravenous methylprednisolone is not significantly beneficial vs oral glucocorticoids in improving visual acuity or survival in patients with giant cell arteritis, and it increases diabetes risk. Medscape Medical News
How Pending Federal Bills Targeting PBMs Might Help Patients
Dr Madelaine A. Feldman discusses how bills might affect access to medications, delink drug list prices from PBMs’ income, and redirect drug manufacturers’ price concessions from payers to patients. MDedge
Coordinated Care Improves Anterior Uveitis in Children
Pediatric patients with anterior uveitis benefitted from seeing a rheumatologist and ophthalmologist together in one visit, as opposed to having separate visits with each specialist. Medscape Medical News
Eyelid Imaging Could Aid Early Diagnosis of Sjögren Disease
Patients with Sjögren disease had more damage to their oil-producing Meibomian glands than people with other varieties of dry eye. Medscape Medical News
Adalimumab Tops Cyclosporine in Preventing Uveitis Relapse
Adalimumab was superior to cyclosporine in preventing uveitis relapse in patients with severe Behçet disease already on corticosteroid therapy, according to randomized, open-label trial results. Medscape Medical News
New Insights into Management of Sjögren-Related Lymphoma
Two European studies reported on a potentially strong predictive biomarker for marginal lymphoma in Sjögren disease and the effectiveness of systemic therapy vs localized treatment or watch and wait. Medscape Medical News
Bimekizumab Lowers Uveitis Rates in Axial Spondyloarthritis
In patients with axial spondyloarthritis, bimekizumab — a dual interleukin-17A/F inhibitor — showed a lower incidence rate of uveitis, suggesting protective effects against acute anterior uveitis. Medscape Medical News
Cigna to Remove AbbVie’s Humira From Some Drug Reimbursement Lists Next Year
Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend… Reuters Health Information
Risks for Hydroxychloroquine Retinopathy Described in Detail
Including over 4670 patients, this is “the largest cohort study to date looking specifically at the association of [HCQ] retinopathy with risk factors,” one expert said. Medscape Medical News
Ultrasound-Aided Diagnosis of GCA Is Accurate, Avoids Biopsy
In a prospective study, all patients diagnosed with giant cell arteritis using ultrasound maintained their diagnosis for up to 2 years of follow-up. Medscape Medical News
FDA OKs High-Concentration of Adalimumab Biosimilar Cyltezo
Unlike the low-concentration formulation of adalimumab-adbm, launched July 1, 2023, this high-concentration version has not yet been granted an interchangeability designation. Medscape Medical News